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Abstract
Introduction: This study aimed to investigate the feasibility of predicting the long–term effects of cholinesterase
inhibitors (ChEI) with common clinical neuroimaging parameters of Alzheimer’s disease, including medial temporal
lobe atrophy (MTA) and white matter hyperintensity (WMH).
Method: A cohort of 353 patients with very mild to moderate Alzheimer’s disease received cholinesterase inhibitors
and were followed for a median of 46.6 months. Baseline clinical data, including age, educational level, Clinical
Dementia Rating (CDR), Taiwanese Mental State Examination (TMSE), and visual scoring for MTA and WMH were
tested as possible predictive factors that influence the survival from a TMSE decline of at least 3 points.
Results: During the follow-up period, 162(46 %) patients had a significant TMSE decline. Patients with age-adjusted
prominent MTA had a significantly shorter TMSE-decline free interval than those without (43.4 ± 4.5 months vs. 68.2
± 9.5 months, log rank test p-value =0.001). However, the severity of WMH does not significantly influence cognitive
outcomes. Cox regression analysis identified that younger age at the time of starting ChEI (p < 0.0005) and higher
total MTA scores (p = 0.002) predict a more rapid TMSE decline under ChEI therapy.
Conclusions: Younger age at the time of starting ChEI and higher visual scoring of MTA may imply a more
advanced Alzheimer’s pathology. WMH load is not a prognostic indicator of treatment response to ChEI.
Introduction
Cholinesterase inhibitors (ChEIs) are the only currently
available medications that may modestly decrease the
cognitive impairment in patients with mild to moderate
Alzheimer’s disease (AD) [1–3]. However, the variable
response between patients, relatively high long-term
costs, and adverse effects make the general application
of ChEIs for all patients with early AD unavailable. Several
studies have tried to identify clinical and neuroimaging
characteristics that might predict the cognitive response
to ChEI therapy [4–8]. However, these studies were often
limited by their small sample size and short period of fol-
low up.
The medial temporal lobe is known to be the initial
site of pathological changes of AD [9]. Previous stud-
ies have shown that the degree of medial temporal at-
rophy (MTA) was associated with the risk of
progression from mild cognitive impairment (MCI) to
AD [10–12], the disease stage [13], and the rate of
cognitive decline [14]. Meanwhile, the association be-
tween MTA and the long-term therapeutic response
to ChEI is not well established. Another neuroimaging
characteristic is the white matter hyperintensity
(WMH), which is viewed by some researchers as an
indicator of the underlying vascular burden that
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contributes to cognitive dysfunction [15, 16]. In
Taiwan, most of our AD patients who receive ChEI
are reimbursed by the National Health Insurance Sys-
tem. A more extensive WMH was one of the exclu-
sion criteria that precluded patients from ChEI paid
for by the national insurance; there was a concern
that this might indicate an underlying vascular path-
ology, in addition to Alzheimer’s pathology [17]. Re-
cent studies have shown an increased burden of
WMH with an increasing severity of AD [18, 19].
However, whether or not the presence of WMH
would influence the cognitive response to ChEI ther-
apy remains undetermined.
We aimed to identify common neuroimaging indica-
tors for the cognitive outcome predictors in AD patients
who received ChEI therapy.
Method
Patient recruitment
We recruited patients with very mild to moderate AD,
Clinical Dementia Rating (CDR) scored 0.5 ~ 2, who re-
ceived both cholinesterase inhibitor therapy and regular
follow-up at the memory clinic of National Taiwan Uni-
versity Hospital, from August 1999 to June 2012. The
diagnosis of AD was made after a comprehensive history
review, neurological examination, laboratory survey, and
neuroimaging study. All of the patients met the diagnos-
tic criteria for probable AD dementia proposed by the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-NDRDA) work
group in 1984 [20]. Before starting the cholinesterase in-
hibitor, clinical data were collected prospectively, includ-
ing basic demographic data, education level, baseline
TMSE (Taiwanese Mini-Mental State Examination)
score [21, 22], and CDR. A standardized regular follow
up of TMSE and CDR was carried out before the trial,
six months after, and annually after starting the cholin-
esterase inhibitor. Patients who were lost to follow-up
within six months of cholinesterase use (seven patients,
2 % of patients initially recruited) were excluded, given
that there were no clinical data available for evaluation
of their response to ChEI. The ChEIs used in this cohort
included donepezil (n = 240, 68 %), rivastigmine (n = 59,
17 %), and galantamine (n = 54, 15 %). The dosages of
ChEIs were titrated up to the standard daily dose of 5 to
10 mg for donepezil, 6–9 mg for rivastigmine, and
16 mg for galantamine (if tolerable); changing from one
ChEI to another was allowed if intolerable side effects
were encountered.
Image acquisition
Brain computed tomography was performed using one of
our multi-detector CT scanners, including GE LightSpeed
16, VCT (GE Healthcare, Milwaukee, WI, USA), SOMA-
TOM Sensation 64, and Emotion 16 (Siemens Medical So-
lutions, Erlangen, Germany). Axial cuts were taken at the
top of the C1 lamina through the top of the calvarium.
Axial images were reconstructed with 5-mm-thick sections
at 5-mm intervals. In some of our subjects, coronal recon-
structed images of 5 mm thickness were also available.
Magnetic resonance imaging (MRI) of the brain was
performed on a 1.5TMR unit, either GE Excite (GE
Healthcare) or MAGNETOM Sonata (Siemens Health-
care). The scanning protocol included axial FLAIR, fast
spin-echo T2-weighted sequences, and a coronal T1WI
or a 3D T1WI. The axial slices were positioned to run
parallel to a line that joins the most inferoanterior and
inferoposterior parts of the corpus callosum and had a
thickness of 5 mm with a gap of 1.5 mm.
Visual scoring for medial temporal atrophy and white
matter hyperintensity
MTA was rated on a coronal view of brain CT or T1-
weighted MRI, using the scoring system proposed by
Scheltens et al. [23]. Each side of the medial temporal
lobe and hippocampus was scored from 0 to 4. A higher
MTA score indicated a higher degree of medial temporal
lobe atrophy.
As the correlation of aging and MTA has been well
established, we defined prominent MTA according to
the patient’s age upon recruitment. A prominent MTA
was defined as a MTA score more than 1 on either side
for patients 75-years-old and under. For patients older
than 75 years, a MTA score more than 2 was required to
define a prominent MTA.
To determine the extent of WMH, a visual scoring
system modified from that suggested by Fazekas et al.
[24] was used. Each brain CT or MRI scan of the FLAIR
series was rated from 0 to 3 on a coronal view, across
two brain areas: frontal and parietal lobes of either side.
The total WMH was scored 0 ~ 12, with the higher score
indicating more extensive white matter hyperintensity.
For WMH scoring, there is generally no accepted cut-
off-point for different age groups. We defined a signifi-
cant WMH if a brain area had a WMH score of 2 or
above. The participants were stratified according to
the severity of WMH, which included: (1) the pres-
ence of a significant WMH in any of the four brain
areas; (2) the number of brain areas with significant
WMH; and (3) the summation of the WMH scores in
all four brain areas.
To determine the inter-rater reliability of visual scor-
ing, 20 MRI or CT scans were rated for MTA and
WMH scoring by two independent raters (YFC and
YWC) who were blinded to the clinical data. The inter-
rater reliability study showed good agreement between
raters for both visual scoring for MTA (intra-class
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correlation coefficient = 0.954) and WMH (intra-class
correlation coefficient = 0.950).
The study was approved by the National Taiwan
University Hospital’s Institutional Review Board. All
investigations were conducted according to the princi-
ples expressed in the Declaration of Helsinki. We ob-
tained written informed consent from the participants
or their proxies.
Statistical analysis
We used the Pearson chi-square test to compare the
between-group differences of categorical variables and
the Mann Whitney U test for numerical variables. The
Log rank test was used for survival data. Stepwise linear
regression analysis was performed separately to evaluate
factors associated with a significant MTA and WMH.
Inter-rater reliability for the visual ratings of WMH and
MTA were measured by intra-class correlation coeffi-
cients. To access the cognitive response to cholinester-
ase inhibitors, we performed a survival analysis; we
plotted the Kaplan-Meier survival curve by setting the
endpoint as a significant TMSE decline from the base-
line of more than 2 points. Patients who passed away or
were lost to follow-up before a clinical evaluation at
six months were excluded. A Cox proportional hazard
model was applied to analyze factors affecting the
time until a significant TMSE decline. Data were ana-
lyzed using the statistical software PASW for win-
dows, version 18.0.
Results
Three hundred and fifty-three patients (217 women and
136 men) with very mild to moderate AD were included
in this study. The median duration of follow up was 46.6
(7.47 ~ 157.4) months. The mean age of the population
was 74.1 ± 10.3 years with a mean education level of
8.9 ± 5.1 years; their mean baseline TMSE score was
19.7 ± 4.1 points and mean CDR score was 0.5 in 195
(55 %) patients, 1 in 129 (36 %) patients, and 2 in
19(5 %) patients (Table 1).
Patients were followed until the study end-point,
death, or loss to follow-up. In summary, 162 (45.8 %) pa-
tients reached an end point (a more than two-point
TMSE decline), 10 (2.8 %) died, and 65 (8.4 %) were lost
to follow-up before a significant TMSE decline.
The mean survival time from a significant TMSE de-
cline of all patients was 56.0 ± 5.2 months. The Kaplan-
Meier survival curve for the TMSE decline did not differ
significantly between patients with or without a signifi-
cant WMH (a dichotomy), defined as a WMH score of
two or more points at any brain area (log rank test
p-value = 0.540). There were no significant differences
in the survival curves between patients stratified by a
total WMH dichotomy of 0–3 versus 4–12 (log rank
test p-value = 0.431); there was no significant difference
among the three groups, comprising a score of 0 to 3, 4 to
7, and 8 to 12 (log rank test p-value = 0.514); in addition,
there was no significant difference among patient groups
stratified by number of areas (a trichotomy) with sig-
nificant WMH of 0, 1 ~ 2, or 3 ~ 4 areas (log rank
test p-value = 0.142).
On the other hand, patients with a prominent MTA
had a shorter TMSE decline-free survival under treat-
ment with a ChEI (Fig. 1a, log rank test p-value = 0.001).
The median survival time from significant TMSE decline
was 68.2 ± 9.5 months for patients without prominent
MTA (n = 217, 61 % censored), compared with 43.4 ±
4.5 months for patients with prominent MTA (n = 136,
43 % censored). When we exclude those patients who
were lost to follow up during the study period, the
remaining 278 patients still showed a significantly
Table 1 Demographic data and neuroimaging characteristics of
the subjects
Baseline characteristics Mean ± SD, or number (%)
Age of starting ChEI (year) 74.1 ± 10.3
Gender, female/male, No. (%) 218/135 (62/38)
Education (year) 8.9 ± 5.1
Baseline TMSE 19.7 ± 4.1
Baseline CDR, No. (%)
0.5 195 (55)
1 129 (36)
2 ~ 3 19 (5)
Total MTA score 3.4 ± 1.7






Prominent MTA adjusted by age, No. (%) 136 (39)
Total WMH score 3.6 ± 3.1
Total WMH score, No. (%)
0 ~ 3 165 (47)
4 ~ 7 125 (35)
8 ~ 12 64 (18)
Number of areas with WMH score > =2
0 237 (67)
1 ~ 2 49 (14)
3 ~ 4 67 (19)
CDR Clinical Dementia Rating, ChEI cholinesterase inhibitor, MTA medial
temporal atrophy, TMSE Taiwanese Mini-Mental State Examination, WMH white
matter hyperintensity
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shorter TMSE decline-free survival for patients with
prominent MTA (log rank test p-value < 0.0005).
To illustrate the effect of individual demographics and
neuroimaging characteristics as risk factors on TMSE
decline-free survival, we performed forward stepwise
Cox regression analysis for independent variables; the
variables included age of starting ChEI, gender, educa-
tional level (by year), baseline TMSE, CDR, total MTA
score, and total WMH score. Younger age at the time of
starting ChEI (p < 0.0005) and higher total MTA score
(p = 0.002) predicted a more rapid decline of TMSE
while receiving ChEI therapy (Table 2). The total WMH
score did not significantly predict the TMSE decline-free
survival.
Because age was a significant confounding factor that
strongly predicted TMSE decline-free survival, we com-
pared the Kaplan-Meier survival curves between differ-
ent age groups. We found that the survival curves differ
significantly for patients 60-years old or less from those
older than 60 years (Fig. 2, log rank test p-value <
0.0005). We performed subgroup analysis, according to
age, in order to compare the significance of WMH and
MTA in separating the Kaplan-Meier survival curve.
The severity of WMH did not separate the survival
curve significantly in patients either younger or older
than 60-years old. On the other hand, a prominent MTA
consistently predicted shorter TMSE-decline free sur-
vival (Fig. 1b, log rank test p-value = 0.019) for patients
60-years old or older (n = 308). The median survival
time was 70.4 ± 7.9 months for patients without
prominent MTA (n = 195, 63 % censored), compared
with 47.4 ± 6.2 months for patients with prominent
MTA (n = 113, 49 % censored). For younger patients
(n = 45), a similar trend was present (Fig. 1c, log rank
test p-value = 0.071). In patients 60-years old or youn-
ger, the median survival time was 35.7 ± 4.2 months
in patients without MTA, compared with 25.3 ±
3.5 months for those with significant MTA.
We performed a multiple stepwise linear regression
analysis by using the total MTA score or total WMH
score as dependent variables to separately identify their
respective predictive factors. The examined independent
variables included the patient’s age, educational level,
baseline CDR, baseline TMSE, and total WMH score or
Fig. 1 TMSE decline-free survival under ChEI therapy. The Kaplan-Meier
survival curves were plotted by setting the endpoint as a significant
TMSE decline from the baseline for more than 2 points, for a all
patients (N = 353, log rank test p-value = 0.001), b patients 60-years old
or older (N = 308, log rank test p-value = 0.019), and c patients younger
than 60-years old (N = 45, log rank test p-value = 0.071). Prominent
MTA predicted shorter TMSE-decline free survival for patients 60-years
old or older when starting ChEI therapy. TMSE Taiwanese Mini-Mental
State Examination, ChEI cholinesterase inhibitor
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total MTA score. We found that a higher total WMH
score, higher educational level, and lower TMSE are as-
sociated with a higher total MTA score (Table 3). On
the other hand, an older age (p < 0.0005), a higher total
MTA score (p < 0.0005), and a higher baseline CDR
score (p = 0.003) are associated with a higher total
WMH score (adjusted R2 0.276). We also examined the
effect of vascular risk factors on the total WMH and
MTA scores. We used age, education level, hypertension
(n = 265), diabetes mellitus (n = 266), hyperlipidemia
(n = 260), and obstructive sleep apnea (n = 228, repre-
sented by snoring) as independent variables in mul-
tiple stepwise linear regression analyses. In addition
to older age (p < 0.0005), we found only the presence
of diabetes mellitus (p = 0.007) was positively associ-
ated with the total WMH score (adjusted R2 0.186).
However, no vascular risk factor was associated with
the total MTA score.
Discussion
In this study, we founded that: (1) for patients with mild
to moderate AD, a lower total MTA score and an older
age predicted a better long term cognitive response to
ChEI therapy, defined by a longer TMSE decline-free
survival; (2) the severity of WMH does not significantly
affect the TMSE decline-free survival; (3) a higher total
MTA score was associated with a higher WMH score,
higher educational level, and a lower baseline TMSE;
and (4) a higher total WMH score was associated
with older age, higher total MTA score, and higher
baseline CDR.
There are two unique features of this study: first, sim-
ple visual scoring for MTA and WMH were used as
neuroimaging markers, which are easily applicable in
daily clinical practice; second, we used long term TMSE
decline-free survival as the endpoint for response to
ChEI treatment, rather than short term cognitive im-
provement, which has been used in most of the previous
studies. We set our outcome measurement as the time
until a TMSE decline of three or more points and our
median follow up time was 46.6 months. Compared with
the short -term cognitive response within months, the
long-term outcome may be of higher clinical importance
for both the patients and the insurance carriers.
In previous studies, volumetric measurements for
medial temporal lobe atrophy, hippocampal atrophy, and
entorhinal cortex thinning were associated with a poorer
cognitive response after ChEI therapy for four or six
months [5, 6]. Findings of our study imply that this ef-
fect may last for several years (median observation
period of approximately four years). Although the volu-
metric measurement is quantitative and draws less con-
cern regarding inter-rater reliability, the technique is
technically demanding and time consuming. This makes
this technique not conveniently applicable in routine
clinical practice. It was shown by Duara et al. that a
higher cut-point for MTA score is required for older
subjects in order to separate AD patients from age-
matched controls [25]. In the original study of Scheltens
et al. [24], a visual scoring of two or more successfully
separated AD patients from age-matched controls; the
median age of the study participants was 72.8 years. In
another study by Duara et al. [26], the authors reported
a mean MTA score of 2.45 on the left side and 2.43 on
the right side in a group of 53 AD patients who had a
mean age of 79.9 years. In this study, we define a “prom-
inent MTA” as a MTA score of three or more for pa-
tients older than 75 years and a MTA score of two or
Table 2 Regression coefficients in Cox proportional hazard models of factors associated with TMSE decline-free survival
Model B SE Exp(B) (95 % CI) P-value
Model I Age of starting ChEI −0.030 0.008 0.971 (0.955 ~ 0.986) <0.0005
Model II Age of starting ChEI −0.035 0.008 0.965 (0.949 ~ 0.981) <0.0005
Total MTA score 0.147 0.047 1.158 (1.056 ~ 1.271) 0.002
CDR Clinical Dementia Rating, ChEI cholinesterase inhibitor, MTA medial temporal atrophy, TMSE Taiwanese Mini-Mental State Examination, WMH white matter
hyperintensity, CI confidence interval; excluded variables in Model II: gender, educational level, baseline TMSE, baseline CDR, and total WMH score; excluded
variables in Model I: gender, educational level, baseline TMSE, baseline CDR, total WMH score, and total MTA score
Fig. 2 TMSE decline-free survival between patients stratified by
different age groups. Patients who started ChEI therapy at the
age of 60 years or younger had a more rapid TMSE decline as
compared to other age groups TMSE Taiwanese Mini-Mental
State Examination, ChEI cholinesterase inhibitor
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more for patients 75 years old or younger. This age-
adjusted cut-off-score for defining “prominent MTA”
subsequently performed better in separating the
TMSE decline-free survival curve under ChEI treat-
ment. This finding is concordant with previous stud-
ies using volumetric measurements; this validates the
visual scoring for MTA measurement as a marker for
the rate of TMSE decline.
Unlike MTA, the role of white matter change in dis-
ease progression and response to ChEI therapy for AD
patients remains controversial [27]. In a study by Con-
nelly et al., the presence of both hypertension and white
matter lesions was associated with a less favorable func-
tional outcome after ChEI therapy for six months [7].
Other studies failed to show a significant correlation be-
tween the severity of WMH and cognitive or functional
outcome after ChEI therapy for three months [4], one
year [28], or nine months or more [8]. On the other
hand, when considering the subcortical hyperintensities
in the cholinergic pathways using the Cholinergic Path-
ways Hyperintensities Scale (CHIPS), Behl et al. showed
that patients in the high CHIPS group had improvement
in executive functioning and working memory tasks after
receiving ChEI therapy for one year [28]. Our study en-
rolled a large sample size and had a relatively long
follow-up period; we observed no significant correlation
between the severity of WMH and ChEI therapeutic re-
sponses, in terms of the TMSE decline-free survival. Re-
garding the global white matter lesion burden, the
WMH scoring cannot differentiate an underlying patho-
logical change or anatomical involvement. For patients
with AD, the white matter changes may be part of the
subcortical changes secondary to the underlying
neurodegenerative process [29]; alternatively, it may be
related to concurrent vascular disease or vascular risk
factors [30–32]. In order to exclude the possible con-
founding effect of vascular risk factors on the total
WMH and MTA scores, we used hypertension, hyperlip-
idemia, diabetes mellitus [31], and obstructive sleep
apnea [32] as independent variables in multiple stepwise
linear regression analyses and found that in addition to
old age, diabetes mellitus is the only risk factor that was
related to total WMH scores. The heterogeneous patho-
physiology underlying global white matter change may
be an important reason why the WMH rating was less
effective in predicting outcomes. Rating the subcortical
involvement of the cholinergic pathway may have more
of a clinical implication, although it may be less applic-
able in daily clinical practice [8, 28].
Linear regressions showed that the severity of MTA
was positively associated with the severity of WMH and
educational level; it was negatively associated with base-
line TMSE. The association of WMH with MTA was in-
dependent of age, TMSE, or CDR. This supports the
possible common neurodegenerative process that under-
lies both MTA and WMH. Another interesting finding
was the association between the severity of MTA and
educational level. Education has been shown to be a pro-
tective factor against the development of MCI and AD
in several epidemiological and longitudinal observational
studies [33, 34]. The cognitive reserve theory suggests
that cognitive activities associated with education, occu-
pational attainment, or leisure may delay the clinical ex-
pression of AD pathology by increasing the neuronal
reserve or neuronal compensation [35]. In our study, a
higher education level was associated with higher MTA
Table 3 Regression coefficients in linear regression models of factors associated with total MTA score
Model B (95 % CI) β P-value Adjusted R2
I Total WMH score 0.202 (0.147 ~ 0.258) 0.361 <0.0005 0.128
II Total WMH score 0.181 (0.124 ~ 0.237) 0.323 <0.0005 0.150
Baseline CDR 0.728 (0.275 ~ 1.182) 0.162 0.002
III Total WMH score 0.186 (0.130 ~ 0.242) 0.332 <0.0005 0.173
Baseline CDR 0.822 (0.371 ~ 1.273) 0.183 <0.0005
Education (year) 0.053 (0.020 ~ 0.086) 0.160 0.001
IV Total WMH score 0.187 (0.133 ~ 0.242) 0.334 <0.0005 0.207
Baseline CDR 0.406 (−0.028 ~ 0.894) 0.090 0.102
Education (year) 0.086 (0.051 ~ 0.122) 0.260 <0.0005
Baseline TMSE −0.099 (−0.149 ~ −0.050) −0.240 <0.0005
V Total WMH score 0.197 (0.143 ~ 0.250) 0.351 <0.0005 0.203
Education (year) 0.089 (0.053 ~ 0.125) 0.268 <0.0005
Baseline TMSE −0.117 (−0.162 ~ −0.072) −0.282 <0.0005
CDR Clinical Dementia Rating, ChEI cholinesterase inhibitor, MTA medial temporal atrophy, TMSE Taiwanese Mini-Mental State Examination, WMH white matter
hyperintensity, CI confidence interval; Variables entered into stepwise linear regression analysis: age of starting ChEI, educational level, baseline TMSE, baseline
CDR, and total WMH score
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scores. This finding is consistent with the cognitive re-
serve theory that more advanced neurodegenerative
pathology may be present in patients with higher edu-
cational levels than those with lower educational level
with the same clinical severity. A negative association
between education and regional cerebral blood flow
in the parietotemporal area [36] or gray matter dens-
ities in the hippocampal area [37] were also shown in
previous studies.
There are some limitations to this study. First, we used
the survival time to a significant TMSE decline, instead
of the rate of TMSE decline as the outcome measure-
ment. Because the study subjects are from a cohort that
received ChEI therapy reimbursed by the National
Health Insurance of Taiwan, most of the patients discon-
tinued ChEI therapy once a significant TMSE decline
was observed as there was a discontinuation of support
from the insurance system. Nevertheless, the duration
before a significant cognitive decline may be more clinic-
ally valuable, as this would be more beneficial to
prolonging the early stages of AD, considering quality-
adjusted life years. Second, we did not control for the
type of ChEI used; this allowed for changing from one
ChEI to another when intolerable side effects were en-
countered. A previous meta-analysis showed no evidence
of any differences in efficacy between different ChEIs
[1]. Clinically, we choose from different ChEIs mainly
based on the side effect profile. Thus, the type of ChEI
was not controlled when evaluating the cognitive re-
sponse. Finally, visual scoring for measurement of the
severity of MTA and WMH was not qualitative and was
associated with a ceiling effect [38]. In addition, there
was no generally accepted age-specific cut-off for WMH
scoring. The high intra-class correlation coefficient sup-
ported good inter-rater agreement in the visual scoring
of either WHM or MTA. We also found a consistent as-
sociation between higher MTA scores and poorer cogni-
tive responses; this was found to be independent of age,
TMSE, CDR, or education, using the Cox proportional
model for survival analysis. On the other hand, the se-
verity of WMH did not significantly affect cognitive re-
sponses; this was true regardless of the fact that we tried
variable stratification strategies, including using the
maximal score of the areas, the summation of the total
scores from all four areas, or the number of areas with
WMH. These findings suggest that the global assess-
ment of WMH is of little, if any, value in predicting cog-
nitive outcomes while on ChEI therapy.
Conclusions
Our results support the application of visual scoring of
MTA as an indicator in predicting long term cognitive
responses to cholinesterase therapy for patients with
mild to moderate Alzheimer’s dementia. On the other
hand, the global assessment of the white matter disease
burden may not contribute significantly to cognitive out-
comes. Furthermore, studies including location or path-
way specific neuroimaging characteristics are required to
identify possible predictive values of different patterns of
WMH in the therapeutic response. At the current stage,
we suggest against the application of the global assess-
ment of the white matter disease burden to exclude pa-
tients from clinically efficacious therapy under the
diagnosis of Alzheimer’s dementia.
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